Safety and Immunogenicity of pneumococcal vaccine VAX-31 in Healthy Infants
To evaluate the safety and tolerability of VAX-31 at 3 dose levels administered to healthy infants at 2, 4, 6, and 12-15 months of age alone and compared to PCV20.
Why this Research Matters
This study is testing a new 31 valent pneumococcal vaccine against the current 20 valent pneumococcal vaccine. The study includes 5 visits, vaccine injections and 3 blood draws. Parents will fill out an e-diary after vaccination.
Who can Participate
Healthy full term infants between 42 and 89 days old
Study ID
Protocol Number: 25-0133
Meet the Team
Principal Investigator